Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

Hepatology Research

Volumn 41, Issue 11, 2011, Pages 1057-1065

  Hyogo, Hideyuki ^a   Ikegami, Tadashi ^e   Tokushige, Katsutoshi ^f   Hashimoto, Etsuko ^f   Inui, Kazuo ^g   Matsuzaki, Yasushi ^e   Tokumo, Hironori ^b   Hino, Fumiaki ^c   Tazuma, Susumu ^d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b JA HIROSHIMA GENERAL HOSPITAL   (Japan)

^c Onomichi General Hospital   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Efficacy; Hyperlipoproteinemia type IIb; Non alcoholic steatohepatitis with dyslipidemia; Pitavastatin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PITAVASTATIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA TYPE 2; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 84856951127     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00849.x     Document Type: Article

References (61)

1. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
2. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
4. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-6.
5. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
6. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
7. Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol 2003; 18: 1115-7.
8. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
9. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
10. Söderberg C, Stål P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
11. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011; 56: 35-45.
12. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 (Suppl 1): 63-9.
13. Musso G, Gambino R, Cassader M, Pagano G. A metaanalysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
14. Look AHEAD Research Group, Wadden TA, West DS, Delahanty L et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 2006; 14: 737-52.
15. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4.
16. Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006; 23: 207-15.
17. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
18. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
19. Kiyici M, Gulten M, Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-8.
20. Hatzitolios A, Savopoulos C, Lazaraki G et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in nonalcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-4.
21. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-6.
22. Dohmen K. Lipoprotein-lowering drugs for liver disease: fenofibrate being potentially useful as an agent. Prog Med 2005; 25: 103-9.
23. Hyogo H, Iwamoto K, Arihiro K et al. Atorvastatin in the treatment of nonalcoholic steatohepatitis. Kanzo 2005; 46: 292-3.
24. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-7.
25. Athyros VG, Mikhailidis DP, Didangelos TP et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83.
26. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of nonalcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-4.
27. Hyogo H, Tazuma S, Arihiro K et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
28. Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology 2009; 56: 1117-21.
29. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-4.
30. Abel T, Fehér J, Dinya E, Eldin MG, Kovács A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with nonalcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6-11.
31. Kimura Y, Hyogo H, Yamagishi S et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-7.
32. Yoneda M, Fujita K, Nozaki Y et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an openlabel, pilot study. Hepatol Res 2010; 40: 613-21.
33. Park H, Shima T, Yamaguchi K et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
34. Whalan DJ. The ethics and morality of clinical trials in man. Med J Aust 1975; 1: 491-4.
35. Hyogo H, Yamagishi S, Iwamoto K et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-9.
36. Lewis JH, Ranard RC, Caruso A et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679-85.
37. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis- report of three cases. J Hepatol 1995; 23: 95-7.
38. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
39. Matsuzawa Y. Japanese Society for the Study of Obesity: new criteria of obesity (in Japanese). J Jpn Soc Study Obes 2000; 6: 18-28.
40. Ricci C, Longo R, Gioulis E et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108-13.
41. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
42. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diab Invest 2010; 1: 212-28.
43. Nathan D. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. International Expert Committee. Diabetes Care 2009; 32: 1327-34.
44. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Hearth Org 2006.
45. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
46. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
47. Funatsu T, Goto M, Kakuta H et al. Reduction in hepatic nonesterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. Biochim Biophys Acta 2002; 1580: 161-70.
48. Isusi E, Aspichueta P, Liza M et al. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis 2000; 153: 283-94.
49. Kainuma M, Fujimoto M, Sekiya N et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006; 41: 971-80.
50. Lu TT, Repa JJ, Mangelsdorf DJ. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 2001; 276: 37735-8.
51. Laffitte BA, Chao LC, Li J et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003; 100: 5419-24.
52. Joseph SB, Laffitte BA, Patel PH et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002; 277: 11019-25.
53. Grefhorst A, Elzinga BM, Voshol PJ et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002; 277: 34182-90.
54. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membranebound transcription factor. Cell 1997; 89: 331-40.
55. Horton JD, Shimomura I. Sterol regulatory elementbinding proteins: activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 1999; 10: 143-50.
56. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-8.
57. Ekstedt M, Franz LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
58. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.
59. Wong VW, Wong GL, Choi PC et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
60. Athyros VG, Tziomalos K, Gossios TD et al. GREACE Study Collaborative Group: safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
61. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136: 1601-8.